Broadcast

e-SPACE CRM 2026 – Day Two

Shelley Zieroth, Shahzeb Khan, João Pedro Ferreira

Broadcast

e-SPACE CRM 2026 – Day One

Shelley Zieroth, Shahzeb Khan, João Pedro Ferreira

Broadcast

Breakthrough Mineralocorticoid Receptor Agonists in Cardiovascular Care

Vijay Chopra, Javed Butler, Dinesh Khullar , et al

Watch time: 1h 4m 2s

About

Hypertension is the most common modifiable risk factor for cardiovascular disease and death, and lowering blood pressure with antihypertensive drugs reduces target organ damage and prevents cardiovascular disease outcomes.

Most hypertensive patients will need a combination of antihypertensive agents to achieve the therapeutic goals. Recent guidelines recommend initiating treatment with two drugs in those patients with a systolic blood pressure >20 mmHg and/or a diastolic blood pressure >10 mmHg above the goals, and in those patients with high cardiovascular risk. In addition, approximately 25% of patients will require three antihypertensive agents to achieve the therapeutic targets.

Articles

Frailty and Cardiovascular Risk

Published:

01 May 2026

Citation:

European Cardiology Review 2026;21:e22.

Pathophysiology, Mechanism, Diagnosis and Management of PAH

Published:

28 January 2026

Citation:

US Cardiology Review 2026;20:e01.

Pregnancy Outcomes in ACHD Patients in Indonesia

Published:

06 November 2025

Citation:

Journal of Asian Pacific Society of Cardiology 2025;4:e35.

Arterial Hypertension: Highlights from ESC 2025

Published:

03 November 2025

Citation:

European Cardiology Review 2025;20:e30.